Particulates or aggregates are a notable challenge for injectables, but there are several methods available to help with identification during formulation and development.
Particulates or aggregates can have a detrimental effect on the efficacy and safety of a biological drug in a number of ways. Aggregation, for example, can lead to, or be a consequence of, misfolded proteins in an inactive state, explains Alex Perieteanu, director, biopharmaceutical services at SGS Agriculture, Food and Life. “This effectively reduces the amount of soluble, active molecule able to perform its intended function,” he says. “Alternatively, even if the molecule remains active, an immune response can result in antibody-mediated neutralization of the protein’s activity or in its bioavailability.”
Certain methods can be employed to identify particulates or aggregates in a biological formulation. Perieteanu states that for insoluble aggregates, it is possible to simply use visual appearance for detection when larger particles have formed. “Light obscuration is employed to determine particle counts in the >2 µm, >5 µm, >10 µm, >25 µm range, and to ensure that requirements for injectables, or ophthalmics are met per United States Pharmacopeia (USP) <787>, USP <788>, or USP <789>,” he adds.
In instances where light obscuration is not feasible due to the extensive formation of bubbles or color, it is more suitable to use microscopic evaluation of sub-visible particles, although, this technique is more labor intensive, Perietenau notes. “Additionally, microflow imaging can look at a similar range of particulate sizes to get more detailed understanding of morphology and distribution,” he says.
If the particulates or aggregates are soluble, it is common practice to use techniques such as sodium dodecyl sulfate-polyacrylamide gel electrophoresis/capillary gel electrophoresis (SDS-PAGE/CGE), size-exclusion chromatography (SEC) using multi-angled light scattering (MALS), and analytical ultracentrifugation, Perieteanu asserts.
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.